Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil

Imagem de Miniatura
Arquivos
art_POLLY_Impact_of_the_COVID19_pandemic_on_the_incidence_2022.PDF (1017.91 KB)
Citações na Scopus
50
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MOSBY-ELSEVIER
Autores
LENNON, Robert P.
Citação
AMERICAN JOURNAL OF INFECTION CONTROL, v.50, n.1, p.32-38, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The impact of COVID-19 on healthcare- associated infections (HCAI) caused by multidrug-resistant (MDR) bacteria that contribute to higher mortality is a growing area of study Methods: This retrospective observational study compares the incidence density (ID) of HCAI caused by MDR bacteria (CRE, CRAB, CRP, MRSA and VRE) pre-COVID (2017-2019) and during the COVID-19 pandemic (2020) in overall hospitalized patients and in intensive care (ICU) units. Results: We identified 8,869 HCAI, of which 2,641 (29.7%) were caused by bacterial MDR, and 1,257 (14.1%) were from ICUs. The overall ID of MDR infections increased 23% (P < .005) during COVID-19. The overall perpathogen analysis shows significant increases in infections by CRAB and MRSA (+108.1%, p<0.005; +94.7%, p<0.005, respectively), but not in CRE, CRP, or VRE. In the ICU, the overall ID of MDR infections decreased during COVID, but that decline was not significant (-6.5%, P = .26). The ICU per-pathogen analysis of ID of infection showed significant increases in CRAB and MRSA (+42.0%, P = .001; +46.2%, P = .04), significant decreases in CRE and CRP (-26.4%, P = .002; -44.2%, P = 0.003, respectively) and no change in VRE. Conclusions: The COVID-19 pandemic correlates to an increase in ID of CRAB and MRSA both in ICU and nonICU setting, and a decrease in ID of CRE and CRP in the ICU setting. Infection control teams should be aware of possible outbreaks of CRAB and MRSA and promote rigorous adherence to infection control measures as practices change to accommodate changes in healthcare needs during and after the pandemic.
Palavras-chave
Healthcare-associated infections, Epidemiology, Multidrug resistant infection, Multidrug resistant bacteria, Carbapenem-resistant , Acinetobacter baumannii , infection, Methicillin-resistant , Staphylococcus aureus , infection
URI
https://observatorio.fm.usp.br/handle/OPI/44463
Referências
  1. [Anonymous], 2020, NAT MICROBIOL, V5, P779, DOI 10.1038/s41564-020-0739-4
  2. Arakawa Y, 2020, MICROBIOL IMMUNOL, V64, P231, DOI 10.1111/1348-0421.12781
  3. Barach P, 2020, PROG PEDIATR CARDIOL, V59, DOI 10.1016/j.ppedcard.2020.101254
  4. Brasil, 2017, MED PREV INF REL ASS
  5. Clancy CJ, 2020, CLIN INFECT DIS, V71, P2736, DOI 10.1093/cid/ciaa524
  6. Clinical and Laboratory Standards Institute, 2020, M100S30 CLIN LAB STA
  7. Cookson C., 2020, SCIENTISTS ALARMED S
  8. Douglas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1557
  9. Garcia-Menino I, 2021, J INFECT PUBLIC HEAL, V14, P50, DOI 10.1016/j.jiph.2020.11.001
  10. Gasperini B, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10010095
  11. Getahun H, 2020, B WORLD HEALTH ORGAN, V98, P442, DOI 10.2471/BLT.20.268573
  12. Gomez-Simmonds A, 2020, OPEN FORUM INFECT DI, V7, pS256
  13. Guimaraes T, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00528-19
  14. Guisado-Gil AB, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9110816
  15. Hsu J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1983
  16. Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8
  17. Langford BJ, 2021, CLIN MICROBIOL INFEC, V27, P520, DOI 10.1016/j.cmi.2020.12.018
  18. Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016
  19. Lucien MAB, 2021, INT J INFECT DIS, V104, P250, DOI 10.1016/j.ijid.2020.12.087
  20. Munita JM, 2016, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 5 EDITION, P481, DOI 10.1128/microbiolspec.VMBF-0016-2015
  21. Murray AK, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01020
  22. National Healthcare Safety Network, CDC NHSN SURV DEF SP, P2021
  23. Paterlini M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1065
  24. Perez S, 2020, MMWR-MORBID MORTAL W, V69, P1827, DOI 10.15585/mmwr.mm6948e1
  25. Rawson TM, 2020, NAT REV MICROBIOL, V18, P409, DOI 10.1038/s41579-020-0395-y
  26. Rawson TM, 2020, J ANTIMICROB CHEMOTH, V75, P1681, DOI 10.1093/jac/dkaa194
  27. Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530
  28. Rawson TM, 2021, CLIN INFECT DIS, V72, P2103, DOI 10.1093/cid/ciaa383
  29. Reardon S, 2020, SCIENCE, DOI 10.1126/science.abc2995
  30. Rossato L, 2020, AM J INFECT CONTROL, V48, P1129, DOI 10.1016/j.ajic.2020.06.192
  31. Sharland M, 2018, LANCET INFECT DIS, V18, P18, DOI 10.1016/S1473-3099(17)30724-7
  32. Tiri B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092744
  33. Tumbarello M, 2012, CLIN INFECT DIS, V55, P943, DOI 10.1093/cid/cis588
  34. WHO, 2019, WHOUHCSDS20196
  35. WHO Pneumonia of Unknown CauseChina, 2020, DIS OUTBREAK NE 0208
  36. World Health Organization (WHO), 2020, RAT US PERS PROT EQ
  37. Yam ELY, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa098

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/49
Artigos e Materiais de Revistas Científicas - ODS/03